This site is intended for healthcare professionals
Skin tissue biopsy under microscope, pink and purple

Roundtable discussion: Biologics in plaque psoriasis

Sponsored by UCB Biopharma SRL
Last updated: 24th Apr 2024
Published: 24th Apr 2024

How much do you know about biologics in plaque psoriasis? Test yourself before and after watching the roundtable discussion.

Which of the following adverse events was identified in plaque psoriasis real-world data?
Persistence of second-line biologics is lowest for which class?
Which of the following patient characteristics is not a consideration when selecting systemic treatments?
Which of the following is not a limitation of real-world studies?

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information 

 

By providing your email address, you are opting in to receive our monthly newsletter.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.

This content has been developed independently by Medthority who previously received educational funding from UCB Biopharma SRL in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.